{"id":"NCT01557166","sponsor":"Novo Nordisk A/S","briefTitle":"Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea: SCALEâ„¢ - Sleep Apnoea","officialTitle":"Effect of Liraglutide in Obese Subjects With Moderate or Severe Obstructive Sleep Apnoea. A 32 Week Randomised, Double-blind, Placebo-controlled, Parallel Group, Multi-centre and Multinational Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-06-07","primaryCompletion":"2013-06-01","completion":"2013-06-17","firstPosted":"2012-03-19","resultsPosted":"2015-02-09","lastUpdate":"2017-11-01"},"enrollment":359,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Metabolism and Nutrition Disorder","Obesity","Obstructive Sleep Apnoea"],"interventions":[{"type":"DRUG","name":"liraglutide","otherNames":[]},{"type":"DRUG","name":"placebo","otherNames":[]}],"arms":[{"label":"Liraglutide 3.0 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This trial is conducted in North America. The aim of the trial is to investigate the effect of liraglutide in obese subjects with sleep apnoea.","primaryOutcome":{"measure":"Change From Baseline in Apnoea-hypopnoea Index (AHI)","timeFrame":"Week 0, Week 32","effectByArm":[{"arm":"Liraglutide 3.0 mg","deltaMin":-12.22,"sd":23.34},{"arm":"Placebo","deltaMin":-6.08,"sd":25.9}],"pValues":[{"comp":"OG000 vs OG001","p":"0.015"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":15},"locations":{"siteCount":42,"countries":["United States","Canada"]},"refs":{"pmids":["27482610","27817208","27005405","28473337","28386912","28950422"],"seeAlso":["http://novonordisk-trials.com"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":176},"commonTop":["Nausea","Headache","Diarrhoea","Upper respiratory tract infection","Nasopharyngitis"]}}